Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer

Next Previous
X
Search
Trial Profile

A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Anastrozole; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil; Tamoxifen; Trastuzumab
  • Indications Early breast cancer; HER2 positive breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FinXX

    • Most Recent Events

    • 06 Jun 2023 Results evaluating characteristics associated with each immune landscape, by deriving samples from this study, pepresented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 05 Feb 2022 Results(n=202) evaluating the BRCA1-like DNA copy number signature, indicative of homologous recombination deficiency, as a predictive biomarker for capecitabine benefit in the TNBC subgroup, published in the British Journal of Cancer
    • 31 May 2020 Results of gene expression analysis and digital spatial profiling from two studies: FinXX trial and from the Mayo Clinic cohort of centrally reviewed TNBC (Leon-Ferre BCRT 2018) assessing specific subtypes and spatial distribution of tumor infiltrating lymphocytes presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top